MA38487A1 - Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) - Google Patents

Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)

Info

Publication number
MA38487A1
MA38487A1 MA38487A MA38487A MA38487A1 MA 38487 A1 MA38487 A1 MA 38487A1 MA 38487 A MA38487 A MA 38487A MA 38487 A MA38487 A MA 38487A MA 38487 A1 MA38487 A1 MA 38487A1
Authority
MA
Morocco
Prior art keywords
age
precursors
sequestering agents
agents
end product
Prior art date
Application number
MA38487A
Other languages
English (en)
Inventor
Farley Stephen Randall Holmes
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38487A1 publication Critical patent/MA38487A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des agents séquestrants de précurseurs d'age comprenant des amines séparées par 2, 3 ou 4 carbones. Les agents séquestrants de précurseurs d'age peuvent être utilisés comme agents pharmaceutiques et dans des compositions pharmaceutiques. Les agents séquestrants de précurseurs d'age sont particulièrement utiles pour lier des précurseurs d'age et des des dicarbonyles alimentaires chez les mammifères dans le tube digestif pour le traitement d'affections telles que la néphropathie diabétique, la néphropathie chronique, l'athérosclérose, l'accident vasculaire cérébral, la cataracte et la maladie d'alzheimer.
MA38487A 2013-03-15 2014-03-12 Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) MA38487A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (fr) 2013-03-15 2014-03-12 Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)

Publications (1)

Publication Number Publication Date
MA38487A1 true MA38487A1 (fr) 2017-12-29

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38487A MA38487A1 (fr) 2013-03-15 2014-03-12 Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (fr)
EP (1) EP2968403A1 (fr)
JP (4) JP2016512830A (fr)
KR (1) KR20150130492A (fr)
CN (1) CN105188718A (fr)
AR (1) AR095593A1 (fr)
AU (2) AU2014235500A1 (fr)
BR (1) BR112015023404A8 (fr)
CA (1) CA2906501A1 (fr)
CL (1) CL2015002624A1 (fr)
CR (1) CR20150545A (fr)
DO (1) DOP2015000221A (fr)
EA (1) EA201591733A1 (fr)
HK (1) HK1220607A1 (fr)
IL (1) IL241406A0 (fr)
MA (1) MA38487A1 (fr)
MX (1) MX2015012843A (fr)
PE (1) PE20151766A1 (fr)
PH (1) PH12015502019A1 (fr)
SG (2) SG11201506413PA (fr)
TN (1) TN2015000390A1 (fr)
TW (1) TW201521744A (fr)
UY (1) UY35441A (fr)
WO (1) WO2014150873A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
US20200188427A1 (en) * 2017-08-31 2020-06-18 Cytosorbents Corporation Reduction of advanced glycation endproducts from bodily fluids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
WO2005032563A1 (fr) * 2003-09-02 2005-04-14 Genzyme Corporation Procede destine a reduire une inflammation vasculaire
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
AU2005214971A1 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
EP2998329A3 (fr) * 2010-02-24 2016-04-06 Relypsa, Inc. Polyvinylamine, polyallylamine et polyéthylèneimine réticulées pour l'utilisation comme séquestrants de l'acide biliaire

Also Published As

Publication number Publication date
WO2014150873A1 (fr) 2014-09-25
US20160024233A1 (en) 2016-01-28
PE20151766A1 (es) 2015-12-11
AU2014235500A1 (en) 2015-11-05
BR112015023404A2 (pt) 2017-07-18
EA201591733A1 (ru) 2016-01-29
MX2015012843A (es) 2016-08-08
PH12015502019A1 (en) 2016-01-11
CL2015002624A1 (es) 2016-03-11
JP2020055850A (ja) 2020-04-09
SG10201707590XA (en) 2017-11-29
AR095593A1 (es) 2015-10-28
TN2015000390A1 (en) 2017-01-03
KR20150130492A (ko) 2015-11-23
AU2019201259A1 (en) 2019-03-14
CN105188718A (zh) 2015-12-23
JP2018135365A (ja) 2018-08-30
EP2968403A1 (fr) 2016-01-20
SG11201506413PA (en) 2015-09-29
JP2022037143A (ja) 2022-03-08
UY35441A (es) 2014-10-31
CR20150545A (es) 2015-12-01
US20180265613A1 (en) 2018-09-20
JP2016512830A (ja) 2016-05-09
HK1220607A1 (zh) 2017-05-12
TW201521744A (zh) 2015-06-16
IL241406A0 (en) 2015-11-30
DOP2015000221A (es) 2015-12-15
CA2906501A1 (fr) 2014-09-25
BR112015023404A8 (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
IN2012DN03312A (fr)
MA38276B1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MY161088A (en) Agonists of gpr40
FR2981934B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
PH12016500814A1 (en) Heteroaryl butanoic acid derivatives
MA33299B1 (fr) Nouvelle formulation de naproxène
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
MX2013003635A (es) Compuestos de n-heteroarilo.
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
WO2015059463A3 (fr) Bêta-caténine
EA201200604A1 (ru) Фармацевтические субстанции на основе митохондриальноадресованных антиоксидантов
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
WO2016011049A3 (fr) Compositions et procédés pour le traitement de maladies à l'aide de composés distribués sous forme de nanoparticules
FR3007039B1 (fr) Procede d'obtention d'un extrait de plante et compositions associees
MA32635B1 (fr) Produit medicamenteux et traitement associe
UA113975C2 (xx) Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти)
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
MA38487A1 (fr) Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)
FR2947729B1 (fr) Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale
MA39406A1 (fr) Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline